Browse > Article
http://dx.doi.org/10.12925/jkocs.2009.26.1.5

Synthesis of a New 4-(Pyridin-3-yl)pyrimidine Derivatives for Anticancer Activity  

Jung, Se-Jin (Life Sciences Research Division, Korea Institute of Science and Technology)
El-Deeb, Ibrahim Mustafa (Department of Biomolecular Science, University of Science and Technology)
Lee, So-Ha (Life Sciences Research Division, Korea Institute of Science and Technology)
Publication Information
Journal of the Korean Applied Science and Technology / v.26, no.1, 2009 , pp. 29-37 More about this Journal
Abstract
This study is focused on the synthesis of urea and amide derivatives particularly, since the amide moiety is an essential binding group at the binding site. Urea derivatives 3-7 and 13-14 were obtained by reaction of 2-aminopyrimidines and other amines with diverse isocyanates in pyridine as a solvent under reflux. The urea derivatives were obtained in low yield because of the highly electron deficient nature of the amino group of the 2-aminopyrimidine. Amide derivatives 8-10 were obtained in moderate yields by reaction of compound 1 with aryl chloride derivatives. Also, arylamine 11 was synthesized by Buchwald-Hartwig amination in moderate yields. Most of the compound did not show good activity against A375P melanoma cells, compared with Sorafenib as control compound.
Keywords
Anticancer activity; 4-(pyridin-3-yl)pyrimidine derivatives; A375P melanoma cells; B-Raf;
Citations & Related Records
연도 인용수 순위
  • Reference
1 G. Manning, D. B. Whyte, R. Martinez,T. Hunter, and S. Sudarsanam, Theprotein kinase complement of the humangenome, Science, 298, 1912 (2002)   DOI   PUBMED   ScienceOn
2 M. A. Pearson and D. Fabbro, Targetingprotein kinases in cancer therapy: asuccess?, Expert Rev. Anticancer Ther.,4, 1113 (2004)   DOI   PUBMED   ScienceOn
3 J. Zimmermann, E. Buchdunger, H. Mett,T. Meyer, N. B. Lydon, and P. Traxler,Phenylarnino-pyrirnidine (P AP)derivatives:a new class of potent andhighly selective PDGF -receptorautophosphorylation inhibitors, Bioorg.Med Chem Lett, 6, 1221 (1996)   DOI   ScienceOn
4 E. Weisberg, P. Manely, j. Mestan, S.Cowan-Jacob, A. Ray, and j. D. Griffin,AMN107 (nilotinib): a novel and selectiveinhibitor of BCR-ABL. Br. J Cancer, 94,1765 (2006)   DOI   ScienceOn
5 W.-S. Huang and W. C. An efficientsynthesis of nilotinib (AMN107).Shakespeare, Synthesis, 14, 2121 (2007)
6 I. Collins and P. Workman, Design anddevelopment of signal transductioninhibitors for cancer treatment: experienceand challenges with kinase targets. CurroSignal Transduction Ther., 1, 13 (2006)
7 J. Klysik, S. j. Theroux, j. M. Sedivy, j.S. Moffit, and K. Boekelheide, Signalingcrossroads: The function of Raf kinaseinhibitory protein in cancer, the centralnervous system and reproduction. Cell.Signalling, 20, 1 (2008)   DOI   ScienceOn
8 H. Adams, S. R. Batten, G. M. Davies,M. B. Duriska, j. C. Jeffery, P. Jensen, j.Lu, G. R. Motson, S. j. Coles, M. B.Hursthouse, and M. D. Ward, New bis-,tris- and tetrakis(pyrazolyI)borate ligandswith 3-pyridyl and 4-pyridyl substituents:synthesis and coordination chemistry.Dalton Trans., 11, 1910 (1910)
9 I. Niculescu-Duvaz, E. Roman, ES. R.Whittaker, R. Kirk, I. j. Scanlon, L. C.Davies, D. Niculescu-Duvaz, R Marais,and C. J. Springer, Novel inhibitors ofB-RAF based on a disubstituted pyrazinescaffold. generation of a nanomolar lead.J Med. Chem, 49, 407 (2006)   DOI   ScienceOn
10 I. M. EI-Deeb, j. C. Ryu, and S. H. Lee,Synthesis of New N-arylpyrirnidin-2-amine derivatives using a palladiumcatalyst, Molecules, 13, 818 (2008)   DOI   ScienceOn
11 X. Xu, R. M. Quiros, P. Gattuso, K. B.Ain, and R. A. Prinz, High prevalence ofb-RAF gene mutation in papillary thyroidcarcinomas and thyroid tumor cell lines.Cancer Res., 63, 4561 (2003)   PUBMED
12 S. M. Wilhelm, C.; Carter, L. Tang, D.Wilkie, A. McNabola, H. Rong, C. Chen,X. Zhang, P. Vincent, M. McHugh, Y.Cao, j. Shujath, S. Gawlak, D. Eveleigh,B. Rowley, L. Liu, L. Adnane, M. Lynch,D. Auclair, I. Taylor, R. Gedrich, A.Voznesensky, B. Riedl, L. E. Post, G.Bollag, and P. A. Trail, BAY 43-9006exhibits broad spectrum oral antitumoractivity and targets the RAF !MEK!ERKpathway and receptor tyrosine kinasesinvolved in tumor progression andangiogenesis, Cancer Res., 64, 7099 (2004)   DOI   ScienceOn
13 S. Klein and A. Levitzki, Signaltransduction therapy for cancer - whithernow?, Curro Signal Transduction Ther., 1,1 (2006)   DOI   ScienceOn
14 A. A. San Juan, StructUral. investigationof PAP derivatives by CoMFA andCoMSIA reveals novel insight towardsinhibition of Bcr-Abl oncoprotein, J Mol.Graphics Modell. 26, 482 (2007)   DOI   ScienceOn
15 S. S. Sridhar, D. Hedley, and L. L. Siu,Raf kinase as a target for anticancertherapeutics, Mol. Cancer Ther., 4, 677(2005)   DOI   ScienceOn